Patents by Inventor Matthew Merrill Carter

Matthew Merrill Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR-associated (Cas) protein
    Patent number: 11939606
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: March 26, 2024
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • CRISPR-associated (Cas) protein
    Patent number: 11932883
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: March 19, 2024
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS
    Publication number: 20220282244
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.
    Type: Application
    Filed: August 20, 2021
    Publication date: September 8, 2022
    Inventors: Andrew Paul MAY, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20220177864
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: February 23, 2022
    Publication date: June 9, 2022
    Inventors: Matthew Merrill CARTER, Paul Daniel DONOHOUE
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 11312953
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 26, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • CRISPR-associated (CAS) protein
    Patent number: 11293011
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 5, 2022
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20210269785
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering.
    Type: Application
    Filed: May 13, 2021
    Publication date: September 2, 2021
    Inventors: Matthew Merrill CARTER, Paul Daniel Donohoue
  • CRISPR-associated (Cas) protein
    Patent number: 11028381
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20210079367
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 18, 2021
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • CRISPR-associated (CAS) protein
    Patent number: 10889808
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 3, 2019
    Date of Patent: January 12, 2021
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • CRISPR-associated (Cas) protein
    Patent number: 10876101
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20200080068
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: November 22, 2019
    Publication date: March 12, 2020
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20190185831
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: March 3, 2019
    Publication date: June 20, 2019
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 10125361
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN
    Publication number: 20180282715
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: March 27, 2018
    Publication date: October 4, 2018
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids
    Publication number: 20180237770
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 23, 2018
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 9909122
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 6, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Donohoue
  • Compositions And Methods Of Nucleic Acid-Targeting Nucleic Acids
    Publication number: 20170327820
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 16, 2017
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 9809814
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: November 7, 2017
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 9803194
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: October 31, 2017
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue